Empirical versus pre-emptive antifungal therapy for persistent febrile neutropenia

Haematologica

Volumn 97, Issue 1, 2012, Pages

  Castagnola, Elio ^a   Haupt, Riccardo ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

Infectious disorders; Invasive mycosis; Therapy

Indexed keywords

ANTIFUNGAL AGENT;

ANTIFUNGAL THERAPY; ANTIMICROBIAL THERAPY; CANCER MORTALITY; CANCER PATIENT; COMPARATIVE STUDY; FEBRILE NEUTROPENIA; HUMAN; LETTER; LEUKEMIA; MYCOSIS; TREATMENT INDICATION;

ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; FEMALE; HUMANS; MALE; MYCOSES;

EID: 84855220166     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.056077     Document Type: Letter

References (2)

1. Pagano L, Caira M, Nosari A, Cattaneo C, Fanci R, Bonini A, et al. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica. 2011;96(9):1366-70.
2. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al. Empirical versus Preemptive Antifungal Therapy for High Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial. Clin Infect Dis. 2009;48(8):1042-51.